Australian MRI-Linac

Teaser text

A unique integration of radiotherapy with real-time MRI-based image guidance that allows cancer and normal tissues to be seen directly during radiotherapy for the first time. Approximately 50% of cancer patients will benefit from such a system that will improve survival, prevent recurrence or relieve the symptoms of their cancer.

Body Text

Competitive advantage

  • One of only four engineering approaches in the world to this problem
  • The Australian MRI-Linac is a unique ‘in-line’ system with the magnetic field parallel to the radiation beam. This results in different radiation dosimetry properties to perpendicular systems

Impact

  • Early international studies suggest the real-time combination of image guidance and radiotherapy results in better survival for poor-outcome cancers
  • The physiologic imaging capabilities of the MRI enable a virtual whole-tumour biopsy prior to and during each treatment, enabling real-time adaptive physiological targeting as a unique way to treat cancer

Successful outcomes

  • First human images were obtained in March 2017
  • First live MRI-Linac treatment in the southern hemisphere was performed using a rat brain tumour model In January 2019
  • Planning for human studies underway

Capabilities and facilities

  • The prototype magnet is a 1 Tesla split system designed to let the high energy X-ray beam travel through an open bore parallel to the magnetic field
  • The research program is embedded into Liverpool Hospital and involves collaboration between numerous universities and scientific organisations
  • Team history of scientific and technological advances in MRI and radiotherapy physics and engineering, as well as the clinical practice of MRI-Linac cancer radiotherapy
  • Team record of research translation resulting in improvements in hardware, workflow, patient outcomes and policy

Our partners

  • The research program is embedded into the Ingham Institute working with Liverpool Hospital and involves collaboration between numerous universities and scientific organisations.